文章摘要
赵子洲,莫 煊,郑银佳,孔雪燕,刘忠纯.精神分裂症患者血清蛋白因子水平与PANSS评分的相关性及其临床意义[J].,2020,(12):2267-2270
精神分裂症患者血清蛋白因子水平与PANSS评分的相关性及其临床意义
The Correlation between Serum Protein Factor Levels and PANSS Scores in Patients with Schizophrenia and Its Clinical Significance
投稿时间:2019-11-06  修订日期:2019-11-29
DOI:10.13241/j.cnki.pmb.2020.12.013
中文关键词: 精神分裂症  蛋白因子  阳性与阴性症状量表评分  生物标志物  相关性
英文关键词: Schizophrenia  Protein factor  Positive and negative symptom scale scores  Biomarkers  Correlation
基金项目:广东省医学科研基金资助项目(B20171269)
作者单位E-mail
赵子洲 武汉大学人民医院精神卫生中心 武汉 湖北 430060 18027307617@126.com 
莫 煊 广州医科大学附属第五医院心理科 广东 广州 510000  
郑银佳 广州医科大学附属第五医院心理科 广东 广州 510000  
孔雪燕 广州医科大学附属第五医院心理科 广东 广州 510000  
刘忠纯 武汉大学人民医院精神卫生中心 武汉 湖北 430060  
摘要点击次数: 10
全文下载次数: 10
中文摘要:
      摘要 目的:观察精神分裂症患者血清蛋白因子与PANSS评分的相关性,探讨血清蛋白因子作为生物标志物评估精神分裂症的可能性。方法:选择2015年5月-2018年7月期间我院收治的68例精神分裂症患者为观察组,根据疗效分为显著组(n=22)、有效组(n=35)、无效组(n=11),同期选择健康体检志愿者68例作为对照组。测定各组神经胶质纤维酸性蛋白(GFAP)、脑源性神经营养因子(BDNF)、神经生长因子(NGF)及钙结合蛋白(S100β)等血清蛋白因子水平,并分析观察组治疗后血清蛋白因子水平与阳性与阴性症状量表(PANSS)评分的相关性。结果:观察组治疗前血清BDNF及NGF水平显著低于对照组,而血清S100β与GFAP水平高于对照组(P<0.05)。不同疗效组治疗前后BDNF、S100β、GFAP水平比较差异有统计学意义(P<0.05),其中显效组的各指标水平最高;不同疗效组治疗前后S100β水平比较差异无统计学意义(P>0.05);与治疗前相比,治疗后不同疗效组BDNF、NGF均降低(P<0.05)。Pearson相关性分析显示,治疗后,血清BNDF水平与PANSS评分呈正相关,GFAP水平与PANSS评分呈负相关(P<0.05),血清NGF、S100β水平与PANSS评分无相关性(P>0.05)。结论:精神分裂症患者在患病早期即存在神经营养不良及神经损伤,血清蛋白因子GFAP、BDNF或可作为辅助评价精神分裂症患者的潜在生物标志物。
英文摘要:
      ABSTRACT Objective: To observe the correlation between serum protein factor and PANSS scores in patients with schizophrenia, and to explore the possibility of serum protein factor as a biomarker for evaluating schizophrenia. Methods: 68 schizophrenic patients admitted to our hospital from May 2015 to July 2018 were selected as observation group, according to the curative effect, the patients were divided into significant group (n=22), effective group (n=35) and invalid group (n=11). At the same time, 68 healthy volunteers were selected as control group. Serum levels of glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and S100 calcium binding protein β (S100β) were measured before and after treatment, and the correlation between serum protein factor levels and positive and negative symptom scale (PANSS) scores in observation group after treatment were analyzed. Results: Before treatment, the levels of serum BDNF and NGF in the observation group were significantly lower than those in the control group, while the levels of serum S100β and GFAP in the observation group were higher than those in the control group (P<0.05). There were significant differences in the levels of BDNF, S100β and GFAP before and after treatment in different therapeutic groups (P<0.05), among them, the significant group had the highest level of each index. There was no significant difference in the level of S100β between different therapeutic groups before and after treatment (P>0.05). Compared with before treatment, the levels of BDNF and NGF in different therapeutic groups decreased after treatment (P<0.05). Pearson correlation analysis showed that after treatment, serum BNDF levels were positively correlated with PANSS scores, while GFAP levels were negatively correlated with PANSS scores (P<0.05), the levels of serum NGF and S100β were not correlated with PANSS scores (P>0.05). Conclusion: Neurological malnutrition and nerve injury occur in the early stage of schizophrenia. Serum protein factors such as GFAP and BDNF may be used as potential biomarkers for evaluating schizophrenia patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭